Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Launched by LEIDEN UNIVERSITY MEDICAL CENTER · Jul 11, 2023
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called selective fetal growth restriction (sFGR) in pregnancies with monochorionic diamniotic twins, meaning the twins share a placenta but have separate amniotic sacs. The goal is to better understand how this condition affects the babies and to improve the way doctors can predict outcomes for these pregnancies. Currently, there isn't a specific treatment for sFGR, so it’s really important to be able to predict if and when the babies might be at risk, which will help parents and doctors make informed decisions about care and monitoring.
To participate in this study, you must have a twin pregnancy where one baby is diagnosed with sFGR before the 28th week of pregnancy. Both parents need to be at least 18 years old and able to give consent for themselves and their babies. Participants can expect to be followed closely until the babies are two years old after birth, which will help researchers gather valuable information about the health and development of the children. This study is unique because it’s the first of its kind to look into these important questions on an international level, and it aims to provide clearer insights and support for families facing this challenging situation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • MCDA twin pregnancy
- • Diagnosis of sFGR before 28+0 weeks of GA (independent of Doppler flows)
- • Pregnant woman ≥ 18 years and able to consent
- • Partner (who has (future) parental responsibility - if applicable) ≥ 18 years and able to consent
- • Written informed consent of both parents (if applicable) for participation in the longitudinal follow-up until 2 years after birth)
- Exclusion Criteria:
- • The presence of lethal anomalies (one or both fetuses)
- • Multiple pregnancy higher order than twins;
- • TTTS/TAPS present at moment of sFGR diagnosis.
About Leiden University Medical Center
Leiden University Medical Center (LUMC) is a prominent academic medical center located in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and high-quality patient care. As a clinical trial sponsor, LUMC focuses on translating scientific discoveries into effective therapies, fostering collaborations between researchers, clinicians, and industry partners. The center is dedicated to conducting rigorous clinical studies across various medical fields, ensuring adherence to ethical standards and regulatory requirements while prioritizing patient safety and outcomes. Through its multidisciplinary approach, LUMC aims to contribute significantly to the understanding and treatment of complex health conditions, driving progress in personalized medicine and improving global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Leuven, , Belgium
Toronto, Ontario, Canada
Leiden, Zuid Holland, Netherlands
Barcelona, , Spain
Stockholm, , Sweden
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported